Li Chang-Fei, Lian Li-Li, Li Qiu-Ru, Jiao Yan
Department of Patient Service Center, The Second Hospital of Jilin University, Changchun 130000, Jilin Province, China.
Department of Neurology, The Second Hospital of Jilin University, Changchun 130000, Jilin Province, China.
World J Gastrointest Surg. 2024 Nov 27;16(11):3408-3412. doi: 10.4240/wjgs.v16.i11.3408.
This editorial discusses the article written by Chen that was published in the latest edition of the . The current study found that programmed cell death 1 ligand 1 (PD-L1) expression is considered as one of the pan-cancer biomarkers of immune checkpoint inhibitors (ICIs) treatment response. Four molecular subtypes are widely used to guide and evaluate the prognosis and diagnosis and treatment of gastric cancer (GC) patients. Clinical trials of ICI treatment including Nivolumab, Pembrolizumab, Avelumab have been conducted for metastatic GC (mGC). The effects of various single agent ICIs on mGC therapy varied. ICIs combined with chemotherapy can indeed bring survival benefits to patients with mGC. Combining ICIs with chemotherapy can give more patients the chance of surgery in the treatment of GC transformation. However, not all PD-L1 positive patients can benefit from it. It is urgent to find better biomarkers to predict the response of ICIs for more precise clinical treatment.
这篇社论讨论了陈撰写并发表在最新一期《》上的文章。当前研究发现，程序性细胞死亡1配体1（PD-L1）表达被视为免疫检查点抑制剂（ICIs）治疗反应的泛癌生物标志物之一。四种分子亚型被广泛用于指导和评估胃癌（GC）患者的预后及诊断与治疗。针对转移性胃癌（mGC）开展了包括纳武利尤单抗、帕博利珠单抗、阿维鲁单抗在内的ICI治疗临床试验。各种单药ICI对mGC治疗的效果各不相同。ICI与化疗联合确实能给mGC患者带来生存益处。在GC转化治疗中，ICI与化疗联合可为更多患者带来手术机会。然而，并非所有PD-L1阳性患者都能从中获益。迫切需要找到更好的生物标志物来预测ICIs的反应，以实现更精准的临床治疗。
